Gilgamesh Pharmaceuticals Analysis: $39M Raised
What is Gilgamesh Pharmaceuticals?
Gilgamesh Pharmaceuticals is a clinical-stage biotech focused on developing innovative therapies for psychiatric diseases, prioritizing rapid-acting and durable treatments over symptom management.
Employees
15
Founded
2019
Revenue
$5M
Product Features & Capabilities
- NMDAR Antagonist: orally bioavailable, rapid-acting, fewer dissociative effects, for depression
- 5-HT2AR Agonists: rapid acting, optimized duration of effect, improved cardiac safety profile, for depression and other indications
- Neuroplastogens: rapid acting, orally bioavailable, non-hallucinogenic
How much Gilgamesh Pharmaceuticals raised
Series B - $39,000,000
December 15, 2022Lead Investor: Not specified in the sources.
Who are the founders of Gilgamesh Pharmaceuticals
Market Focus
Gilgamesh Pharmaceuticals primarily focuses on the biotechnology industry, specifically in the clinical-stage neuroscience sector, developing innovative therapies for psychiatric diseases.
Investors
- National Institute on Drug Abuse (NIDA)
- 10X Capital
- Alumni Ventures
- Ayuh Ventures
- PsyMed Ventures
- Prime Movers Lab
- Palo Santo
- Negev Capital
- Route 66 Ventures
- JLS Fund
- Satori
- Gron Ventures
- Noetic Psychedelic Fund
Business Model
Collaborations and funding from partnerships drive revenue through licensing and clinical trials.
Competitors Overview
Gilgamesh Pharmaceuticals operates in the neuroscience biotech sector, focusing on innovative treatments for psychiatric diseases. Its main competitors include:
- ATAI Life Sciences: A clinical-stage biopharmaceutical company dedicated to developing effective mental health treatments. ATAI emp
See something that needs updating? Suggest edits to this profile.